Home > Publications database > Serum selenoprotein P concentrations and cardiovascular disease: results from a large, prospective cohort study of older German adults. > print

001     303240
005     20250829115148.0
024 7 _ |a 10.1016/j.freeradbiomed.2025.07.039
|2 doi
024 7 _ |a pmid:40738180
|2 pmid
024 7 _ |a 0891-5849
|2 ISSN
024 7 _ |a 1873-4596
|2 ISSN
037 _ _ |a DKFZ-2025-01586
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Cui, Zhixin
|0 P:(DE-He78)a9f5a6e80270aef6347a340d52c893c1
|b 0
|e First author
|u dkfz
245 _ _ |a Serum selenoprotein P concentrations and cardiovascular disease: results from a large, prospective cohort study of older German adults.
260 _ _ |a New York, NY [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756461072_12782
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C070#LA:C070# / Volume 239, November 2025, Pages 270-279
520 _ _ |a Studies on the association of selenoprotein P (SELENOP) with cardiovascular outcomes yielded inconsistent results. We assessed the association of SELENOP serum levels with cardiovascular disease (CVD), stroke and coronary heart disease (CHD) in CVD-free adults and the association with CVD mortality in CVD patients.Serum SELENOP concentrations were measured at baseline and 5-year follow-up in 6,600 CVD-free participants and 1,729 CVD patients aged 50-74 years from the German ESTHER study. Multivariable Cox models were performed.During 17 years of follow-up, 1,837 CVD-free participants developed CVD, of whom 675 had a stroke and 1,153 were diagnosed with CHD, and 352 CVD patients died from CVD. In the multivariable Cox model, CVD-free participants in the lowest SELENOP quartile had a 1.5-fold higher stroke risk than those in the highest quartile (HR [95%CI], 1.58 [1.17-2.12]). Associations with CVD incidence were only observed in patients with hypertension (HR [95%CI], 1.21 [1.03-1.41]) or diabetes (HR [95%CI], 1.36 [1.01-1.83]). No association was observed between SELENOP concentrations and CHD incidence. Furthermore, CVD patients in the lowest SELENOP quartile had an almost 2-fold increased CVD mortality compared to the rest (HR [95%CI], 1.85 [1.31-2.60]).Low serum SELENOP concentrations were associated with an increased risk of stroke in subjects free of CVD and with CVD mortality among CVD patients. The association of SELENOP concentrations with CVD incidence was restricted to patients with hypertension or diabetes. Well-designed trials are required to assess potential preventive effects of selenium supplementation.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cardiovascular Diseases
|2 Other
650 _ 7 |a Cohort Studies
|2 Other
650 _ 7 |a Coronary Disease
|2 Other
650 _ 7 |a Mortality
|2 Other
650 _ 7 |a Selenoprotein P
|2 Other
650 _ 7 |a Stroke
|2 Other
700 1 _ |a Schomburg, Lutz
|b 1
700 1 _ |a Holleczek, Bernd
|b 2
700 1 _ |a Hybsier, Sandra
|b 3
700 1 _ |a Köhrle, Josef
|b 4
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 5
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 6
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.freeradbiomed.2025.07.039
|g p. S0891584925008548
|0 PERI:(DE-600)1483653-1
|p 270-279
|t Free radical biology and medicine
|v 239
|y 2025
|x 0891-5849
909 C O |p VDB
|o oai:inrepo02.dkfz.de:303240
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)a9f5a6e80270aef6347a340d52c893c1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FREE RADICAL BIO MED : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FREE RADICAL BIO MED : 2022
|d 2025-01-02
920 2 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie der Krebsfrüherkennung
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie der Krebsfrüherkennung
|x 0
920 0 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie der Krebsfrüherkennung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21